Ernexa Therapeutics (ERNAW) Assets Average (2011 - 2026)

Ernexa Therapeutics has reported Assets Average for 16 years, with the latest figure at $8.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 58.57% year-over-year to $8.2 million; the trailing twelve-month figure through Mar 2026 stood at $8.2 million (up 58.57% YoY), and the FY2025 full-year result was $5.6 million, down 79.59% from the prior year.
• Assets Average for Q1 2026 stood at $8.2 million, up from $6.0 million in the prior quarter.
• The five-year high for Assets Average was $50.7 million in Q4 2023, with the low at $5.2 million in Q1 2025.
• Historically, Assets Average has averaged $24.9 million across 5 years, with a median of $23.9 million in 2022.
• Annual changes were most pronounced in 2024 — Assets Average soared 164.23% — and 2025, when it plunged 89.55%.
• Ernexa Therapeutics' Assets Average stood at $21.6 million in 2022, then soared by 134.65% to $50.7 million in 2023, then tumbled by 87.19% to $6.5 million in 2024, then decreased by 7.55% to $6.0 million in 2025, then surged by 36.41% to $8.2 million in 2026.
• The last three Assets Average figures came in at $8.2 million (Q1 2026), $6.0 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.